프리시젼바이오

335810KOSDAQ의료용 기기 제조업

46.0 / 100

Reference Date: 2026-04-13

Financial Score12.5 / 40

News Sentiment12.5 / 25

Momentum11.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is low with sound financial health but ROE is below the industry average. Slightly up 3.9% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

PrecisionBio is a specialized IVD company that develops diagnostic solutions using time-resolved fluorescence and gold absorption technologies for critical conditions such as cardiovascular and infectious diseases. Its key products include the Exdia TRF analyzer and cartridges, as well as clinical chemistry diagnostic products like Exdia PT10/PT10S. The company expanded into clinical chemistry diagnostics in 2021 and is developing a digital healthcare platform to integrate its diagnostic tools with digital services.

Number of Employees

97people

Average Salary

54.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 26.524.0Point

PBR

1.52Industry Average 1.704.0Point

In line with industry avg

ROE

-34.29Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

8.31Industry Average 10.954.0Point

In line with industry avg

Trend 2023~20250.5 / 10 points

Revenue Growth Rate

0.5 / 3

Avg ▼1.0% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼5.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -24.4% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (14%, downtrend)

Current 2,270Won52-week high 3,52052-week low 2,065

1-month return4.0Point

1m +3.89% (slight rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral정기주주총회결과2026-03-25
Neutral사업보고서 (2025.12)2026-03-17
Neutral감사보고서제출2026-03-17